BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 30197047)

  • 21. Diagnostic Accuracy of T1-Weighted Dynamic Contrast-Enhanced-MRI and DWI-ADC for Differentiation of Glioblastoma and Primary CNS Lymphoma.
    Lin X; Lee M; Buck O; Woo KM; Zhang Z; Hatzoglou V; Omuro A; Arevalo-Perez J; Thomas AA; Huse J; Peck K; Holodny AI; Young RJ
    AJNR Am J Neuroradiol; 2017 Mar; 38(3):485-491. PubMed ID: 27932505
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Value of Vascular Permeability Estimates Using Dynamic Susceptibility Contrast MRI: Improved Diagnostic Performance in Distinguishing Hypervascular Primary CNS Lymphoma from Glioblastoma.
    Lee B; Park JE; Bjørnerud A; Kim JH; Lee JY; Kim HS
    AJNR Am J Neuroradiol; 2018 Aug; 39(8):1415-1422. PubMed ID: 30026384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiparametric-MRI-Based Radiomics Model for Differentiating Primary Central Nervous System Lymphoma From Glioblastoma: Development and Cross-Vendor Validation.
    Xia W; Hu B; Li H; Geng C; Wu Q; Yang L; Yin B; Gao X; Li Y; Geng D
    J Magn Reson Imaging; 2021 Jan; 53(1):242-250. PubMed ID: 32864825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differentiation of Primary Central Nervous System Lymphoma and High-Grade Glioma with Dynamic Susceptibility Contrast-Derived Metrics: Pilot Study.
    Chaganti J; Taylor M; Woodford H; Steel T
    World Neurosurg; 2021 Jul; 151():e979-e987. PubMed ID: 34020062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential diagnosis of parotid gland tumours: Application of SWI combined with DWI and DCE-MRI.
    Xu Z; Chen M; Zheng S; Chen S; Xiao J; Hu Z; Lu L; Yang Z; Lin D
    Eur J Radiol; 2022 Jan; 146():110094. PubMed ID: 34906852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does adding FDG-PET to MRI improve the differentiation between primary cerebral lymphoma and glioblastoma? Observer performance study.
    Makino K; Hirai T; Nakamura H; Murakami R; Kitajima M; Shigematsu Y; Nakashima R; Shiraishi S; Uetani H; Iwashita K; Akter M; Yamashita Y; Kuratsu J
    Ann Nucl Med; 2011 Jul; 25(6):432-8. PubMed ID: 21404136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved performance of non-preloaded and high flip-angle dynamic susceptibility contrast perfusion-weighted imaging sequences in the presurgical differentiation of brain lymphoma and glioblastoma.
    Wang F; Zhou X; Chen R; Kang J; Yang X; Lin J; Liu F; Cao D; Xing Z
    Eur Radiol; 2023 Dec; 33(12):8800-8808. PubMed ID: 37439934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinguishing Tumor Recurrence From Radiation Necrosis in Treated Glioblastoma Using Multiparametric MRI.
    Feng A; Yuan P; Huang T; Li L; Lyu J
    Acad Radiol; 2022 Sep; 29(9):1320-1331. PubMed ID: 34896001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differentiating Glioblastoma from Primary Central Nervous System Lymphoma: The Value of Shaping and Nonenhancing Peritumoral Hyperintense Gyral Lesion on FLAIR Imaging.
    Wang P; Shi YH; Li JY; Zhang CZ
    World Neurosurg; 2021 May; 149():e696-e704. PubMed ID: 33548537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients.
    Kim JY; Park JE; Jo Y; Shim WH; Nam SJ; Kim JH; Yoo RE; Choi SH; Kim HS
    Neuro Oncol; 2019 Feb; 21(3):404-414. PubMed ID: 30107606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonenhancing peritumoral hyperintense lesion on diffusion-weighted imaging in glioblastoma: a novel diagnostic and specific prognostic indicator.
    Kolakshyapati M; Adhikari RB; Karlowee V; Takayasu T; Nosaka R; Amatya VJ; Takeshima Y; Akiyama Y; Sugiyama K; Kurisu K; Yamasaki F
    J Neurosurg; 2018 Mar; 128(3):667-678. PubMed ID: 28362236
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparative study of multimodal magnetic resonance in the differential diagnosis of acquired immune deficiency syndrome related primary central nervous system lymphoma and infection.
    Li J; Xue M; Yan S; Guan C; Xie R; Chen B
    BMC Infect Dis; 2021 Feb; 21(1):165. PubMed ID: 33568094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diffusion-weighted MRI combined with susceptibility-weighted MRI: added diagnostic value for four common lateral ventricular tumors.
    Yu Y; Zhang H; Xiao Z; She D; Xing Z; Yang X; Cao D
    Acta Radiol; 2018 Aug; 59(8):980-987. PubMed ID: 29065704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differentiation between glioblastoma and primary CNS lymphoma: application of DCE-MRI parameters based on arterial input function obtained from DSC-MRI.
    Kang KM; Choi SH; Chul-Kee P; Kim TM; Park SH; Lee JH; Lee ST; Hwang I; Yoo RE; Yun TJ; Kim JH; Sohn CH
    Eur Radiol; 2021 Dec; 31(12):9098-9109. PubMed ID: 34003350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differentiating Between Primary Central Nervous System Lymphomas and Glioblastomas: Combined Use of Perfusion-Weighted and Diffusion-Weighted Magnetic Resonance Imaging.
    Makino K; Hirai T; Nakamura H; Kuroda JI; Shinojima N; Uetani H; Kitajima M; Yano S
    World Neurosurg; 2018 Apr; 112():e1-e6. PubMed ID: 29104150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differentiation of high-grade glioma and primary central nervous system lymphoma: Multiparametric imaging of the enhancing tumor and peritumoral regions based on hybrid
    Zhang S; Wang J; Wang K; Li X; Zhao X; Chen Q; Zhang W; Ai L
    Eur J Radiol; 2022 May; 150():110235. PubMed ID: 35290912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differentiation of grade II/III and grade IV glioma by combining "T1 contrast-enhanced brain perfusion imaging" and susceptibility-weighted quantitative imaging.
    Saini J; Gupta PK; Sahoo P; Singh A; Patir R; Ahlawat S; Beniwal M; Thennarasu K; Santosh V; Gupta RK
    Neuroradiology; 2018 Jan; 60(1):43-50. PubMed ID: 29090331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
    Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
    BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differentiation between primary central nervous system lymphoma and glioblastoma: a comparative study of parameters derived from dynamic susceptibility contrast-enhanced perfusion-weighted MRI.
    Nakajima S; Okada T; Yamamoto A; Kanagaki M; Fushimi Y; Okada T; Arakawa Y; Takagi Y; Miyamoto S; Togashi K
    Clin Radiol; 2015 Dec; 70(12):1393-9. PubMed ID: 26382744
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glioblastoma and primary central nervous system lymphoma: Preoperative differentiation by using MRI-based 3D texture analysis.
    Xiao DD; Yan PF; Wang YX; Osman MS; Zhao HY
    Clin Neurol Neurosurg; 2018 Oct; 173():84-90. PubMed ID: 30092408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.